Without a rigorous discussion of the pros and cons of QbD, its tremendous benefits will be lost.
Lynn Torbeck
Advertisement
Lynn Torbeck is a statistician at Torbeck and Assoc.
Articles by Lynn Torbeck
Advertisement
Latest Updated Articles
QbD: Convincing the SkepticsPublished: May 1st 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
